{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:30:40Z","timestamp":1767205840466,"version":"build-2238731810"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We analyzed different patient subgroups to determine optimal maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 226 NDMM patients in our center were included in the study. The characteristics, survival, and adverse reactions were compared among patients who received maintenance therapy or not, and patients who received proteasome inhibitors (PIs) or immunomodulators (IMiDs) maintenance. The survival of different maintenance durations of bortezomib-based regimens was also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The maintenance therapy not only upgraded more patient responses (34.3\n                      <jats:italic>vs<\/jats:italic>\n                      13.3%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006), but also significantly prolonged their progression-free survival (PFS) (median PFS: 41.1\n                      <jats:italic>vs<\/jats:italic>\n                      10.5 months,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and overall survival (OS) (median OS: not reached\n                      <jats:italic>vs<\/jats:italic>\n                      38.6 months,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Compared with IMiDs, the PFS (median PFS: 43.7\n                      <jats:italic>vs<\/jats:italic>\n                      38.5 months,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.034) and OS (median OS: not reached\n                      <jats:italic>vs<\/jats:italic>\n                      78.5 months,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.041) were both enhanced by PIs maintenance. Patients younger than 65 years who received PIs had a significantly prolonged OS (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.032). Patients achieving only a partial response (PR) after induction and consolidation therapy had significantly longer PFS and OS after PIs maintenance compared to IMiDs (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.007, 0.002). High-risk patients (ISS 2\u20133, DS 2\u20133, and RISS 2\u20133) given PIs maintenance benefit from a prolonged PFS (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002, 0.02, 0.06) and OS (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.059, 0.047, 0.044, respectively) compared with IMiDs therapy. OS was significantly prolonged in patients who received \u2265 12 months of bortezomib-based maintenance therapy compared to those who were treated for &amp;lt; 12 months (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), but no difference was observed in OS between patients who received 12 to 24 or \u2265 24 months of bortezomib-based maintenance therapy (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.292).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PIs maintenance was superior to IMiDs in overall PFS and OS. The beneficial effect was most evident in patients achieving PR after induction and consolidation therapy, and in high-risk patients. Moreover, younger patients also benefited from PIs maintenance with an increased OS. A bortezomib-based maintenance therapy duration of 12 to 24 months after induction and consolidation therapy produced satisfactory OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.665217","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T05:15:26Z","timestamp":1623647726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaoyan","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three Pethema\/Gem Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1283","article-title":"Analysis of Long-Term Survival in Multiple Myeloma After First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Sustained Response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients With Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone With Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance Therapy With Thalidomide Improves Survival in Patients With Multiple Myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222539","article-title":"A Randomized Phase 3 Study on the Effect of Thalidomide Combined With Adriamycin, Dexamethasone, and High-Dose Melphalan, Followed by Thalidomide Maintenance in Patients With Multiple Myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.212","article-title":"Fixed Duration vs Continuous Therapy in Multiple Myeloma","volume":"2017","author":"Ludwig","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.04.001","article-title":"Thalidomide Maintenance Therapy for Patients With Multiple Myeloma: Meta-Analysis","volume":"36","author":"Kagoya","year":"2012","journal-title":"Leuk Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From Transplant to Novel Cellular Therapies in Multiple Myeloma: European Myeloma Network Guidelines and Future Perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-020-0298-1","article-title":"Bortezomib-based Consolidation or Maintenance Therapy for Multiple Myeloma: A Meta-Analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III Hovon-65\/ GMMG-HD4 Trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib Before and After High-Dose Therapy in Myeloma: Long-Term Results From the Phase III Hovon-65\/Gmmg-HD4 Trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in Recurrent and\/or Refractory Multiple Myeloma. Initial Clinical Experience in Patients With Impared Renal Function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib Before and After Autologous Stem Cell Transplantation Overcomes the Negative Prognostic Impact of Renal Impairment in Newly Diagnosed Multiple Myeloma: A Subgroup Analysis From the HOVON-65\/GMMG-HD4 Trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib Consolidation After Autologous Stem Cell Transplantation in Multiple Myeloma: A Nordic Myeloma Study Group Randomized Phase 3 Trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second Primary Malignancies With Lenalidomide Therapy for Newly Diagnosed Myeloma: A Meta-Analysis of Individual Patient Data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.561601","article-title":"Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data","volume":"11","author":"He","year":"2020","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13238","article-title":"Subcutaneous Bortezomib Combined With Weekly Cyclophosphamide and Dexamethasone is an Efficient and Well Tolerated Regime in Newly Diagnosed Multiple Myeloma","volume":"169","author":"Ong","year":"2015","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e99174","DOI":"10.1371\/journal.pone.0099174","article-title":"The Choice of Regimens Based on Bortezomib for Patients With Newly Diagnosed Multiple Myeloma","volume":"9","author":"He","year":"2014","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S261887","article-title":"Real-World Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-Center Study in China","volume":"12","author":"Ding","year":"2020","journal-title":"Cancer Manag Res"}],"updated-by":[{"DOI":"10.3389\/fonc.2021.740715","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.665217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:08:48Z","timestamp":1630721328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.665217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":30,"alternative-id":["10.3389\/fonc.2021.665217"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.665217","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"article-number":"665217"}}